Obesity and increased risk of esophageal adenocarcinoma

References

• Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58
   PubMed Web of Science ®Google Scholar
• Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol 2015;12:243-8
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84
   PubMed Web of Science ®Google Scholar
• Reynolds JV, Donohoe CL, McGillycuddy E, et al. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center. J Thorac Cardiovasc Surg 2012;143:1130-7 e1
   PubMed Web of Science ®Google Scholar
• Howlader N, Krapcho M, Garshell J, et al. SEER Cancer statistics review, 1975-2012, National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2012/ based on November 2014 SEER data submission, posted to the SEER web site, April 2015 [Last accessed 15 July 2015]
   Google Scholar
• Cancer Research UK Publications. Available from: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/survival#heading-Two [Last accessed 15 July 2015]
   Google Scholar
• Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706-18
   PubMed Web of Science ®Google Scholar
• Anggiansah R, Sweis R, Anggiansah A, et al. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2013;37:555-63
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100:1243-50
   PubMed Web of Science ®Google Scholar
• Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes 2008;32:S56-S9
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments association with metabolic risk factors in the Framingham heart study. Circulation 2007;116:39-48
   PubMed Web of Science ®Google Scholar
• Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273-82
   PubMed Web of Science ®Google Scholar
• Rossner S, Bo WJ, Hiltbrandt E, et al. Adipose tissue determinations in cadavers–a comparison between cross-sectional planimetry and computed tomography. Int J Obes 1990;14:893-902
   PubMed Web of Science ®Google Scholar
• Rankinen T, Kim SY, Perusse L, et al. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999;23:801-9
   PubMed Web of Science ®Google Scholar
• Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8
   PubMed Web of Science ®Google Scholar
• Lemieux S, Prud’homme D, Bouchard C, et al. A single threshold value of waist girth identifies normal weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996;64:685-93
   PubMed Web of Science ®Google Scholar
• Han TS, Seidell JC, Currall JE, et al. The influences of height and age on waist circumference as an index of adiposity in adults. Int J Obes Relat Metab Disord 1997;21:83-9
   PubMed Web of Science ®Google Scholar
• O’Doherty MG, Freedman ND, Hollenbeck AR, et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH–AARP Diet and Health Study. Gut 2012;61:1261-8
   PubMed Web of Science ®Google Scholar
• MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006;118:2628-31
   PubMed Web of Science ®Google Scholar
• Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1399-412. e7
   PubMed Web of Science ®Google Scholar
• Behrens G, Jochem C, Keimling M, et al. The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis. Eur J Epidemiol 2014;29:151-70
   PubMed Web of Science ®Google Scholar
• Barrett N. Chronic peptic ulcerz of the œophagus and ‘œsophagitis’. Br J Surg 1950;38:175-82
   PubMed Web of Science ®Google Scholar
• Reid BJ, Li X, Galipeau PC, et al. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87-101
   PubMed Web of Science ®Google Scholar
• Conio M, Cameron AJ, Chak A, et al. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett’s oesophagus. Lancet Oncol 2005;6:311-21
   PubMed Web of Science ®Google Scholar
• Westhoff B, Brotze S, Weston A, et al. The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005;61:226-31
   PubMed Web of Science ®Google Scholar
• Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am J Gastroenterol 2010;105:1730-7
   Web of Science ®Google Scholar
• Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354-9
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31
   PubMed Web of Science ®Google Scholar
• Rex DK, Cummings OW, Shaw M, et al. Screening for barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7
   PubMed Web of Science ®Google Scholar
• Balasubramanian G, Singh M, Gupta N, et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 2012;107:1655-61
   PubMed Web of Science ®Google Scholar
• Ward EM, Wolfsen HC, Achem SR, et al. Barrett’s esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 2006;101:12-17
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology 2007;133:34-41; quiz 311
   PubMed Web of Science ®Google Scholar
• Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008;247:909-15
   PubMedGoogle Scholar
• Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1399-412 e7
   PubMed Web of Science ®Google Scholar
• Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 2007;13:1585-94
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008;17:352-8
   PubMed Web of Science ®Google Scholar
• Steffen A, Schulze MB, Pischon T, et al. Anthropometry and esophageal cancer risk in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2009;18:2079-89
   PubMed Web of Science ®Google Scholar
• O’Doherty MG, Freedman ND, Hollenbeck AR, et al. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut 2012;61:1261-8
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Kao JY, Madanick RD, et al. Association of adiponectin multimers with Barrett’s oesophagus. Gut 2009;58:1583-9
   PubMed Web of Science ®Google Scholar
• Mokrowiecka A, Daniel P, Jasinska A, et al. Serum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett’s esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD. Hepatogastroenterology 2012;59:2395-9
   PubMed Web of Science ®Google Scholar
• Jacobson BC, Chan AT, Giovannucci EL, et al. Body mass index and Barrett’s oesophagus in women. Gut 2009;58:1460-6
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol 2013;108:353-62
   PubMed Web of Science ®Google Scholar
• Kramer JR, Fischbach LA, Richardson P, et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett’s esophagus in white men. Clin Gastroenterol Hepatol 2013;11:373-81 e1
   PubMed Web of Science ®Google Scholar
• Kendall BJ, Macdonald GA, Hayward NK, et al. The risk of Barrett’s esophagus associated with abdominal obesity in males and females. Int J Cancer 2013;132:2192-9
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Dahlkemper A, Kao JY, et al. A pilot study of the association of low plasma adiponectin and Barrett’s esophagus. Am J Gastroenterol 2008;103:1358-64
   PubMed Web of Science ®Google Scholar
• Greer KB, Thompson CL, Brenner L, et al. Association of insulin and insulin-like growth factors with Barrett’s oesophagus. Gut 2012;61:665-72
   PubMed Web of Science ®Google Scholar
• Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett’s esophagus. Gastroenterology 2007;133:403-11
   PubMed Web of Science ®Google Scholar
• Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 2003;32:645-50
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut 2007;56:749-55
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:2619-28
   PubMed Web of Science ®Google Scholar
• Cai N, Ji GZ, Fan ZN, et al. Association between body mass index and erosive esophagitis: a meta-analysis. World J Gastroenterol 2012;18:2545
   PubMed Web of Science ®Google Scholar
• Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706-18
   PubMed Web of Science ®Google Scholar
• O’Sullivan KE, Phelan JJ, O’Hanlon C, et al. The role of inflammation in cancer of the esophagus. Expert Rev Gastroenterol Hepatol 2014;8:749-60
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Tran T, Richardson P, et al. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006;41:887-91
   PubMed Web of Science ®Google Scholar
• Nocon M, Labenz J, Jaspersen D, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol 2007;22:1728-31
   PubMed Web of Science ®Google Scholar
• Greene CL, Worrell SG, DeMeester TR. Rat reflux model of esophageal cancer and its implication in human disease. Ann Surg 2015. [Epub ahead of print]
   Google Scholar
• Fitzgerald RC. Barrett’s oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 2005;54(Suppl 1):i21-6
   PubMed Web of Science ®Google Scholar
• Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2013;11:382-8
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L, Fennerty MB, et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011;34:146-65
   PubMed Web of Science ®Google Scholar
• Nishijima K, Miwa K, Miyashita T, et al. Impact of the biliary diversion procedure on carcinogenesis in Barrett’s esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg 2004;240:57-67
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen X, Bajpai M, et al. Cellular origins and molecular mechanisms of Barrett’s esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci 2013;1300:187-99
   PubMed Web of Science ®Google Scholar
• Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004;25:317-23
   PubMed Web of Science ®Google Scholar
• O’Riordan JM, Abdel-latif MM, Ravi N, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 2005;100:1257-64
   PubMed Web of Science ®Google Scholar
• Hopwood D, Bateson MC, Milne G, et al. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut 1981;22:306-11
   PubMed Web of Science ®Google Scholar
• Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999;44:598-602
   PubMed Web of Science ®Google Scholar
• Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett’s esophagus. Oncogene 1996;13:1867-73
   PubMed Web of Science ®Google Scholar
• Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9
   PubMedGoogle Scholar
• Bajpai M, Aviv H, Das KM. Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett’s epithelium. Mol Cytogenet 2012;5:43
   PubMedGoogle Scholar
• Dulak AM, Stojanov P, Peng S, et al. Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45(5):478-86
   PubMed Web of Science ®Google Scholar
• Weaver JMJ, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-43
   PubMed Web of Science ®Google Scholar
• Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905
   PubMed Web of Science ®Google Scholar
• Weaver JM, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-43
   PubMed Web of Science ®Google Scholar
• Rustgi AK. Models of esophageal carcinogenesis. Semin Oncol 2006;33:S57-8
   PubMed Web of Science ®Google Scholar
• Mann NS, Tsai MF, Nair PK. Barrett’s esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 1989;84:1494-6
   PubMed Web of Science ®Google Scholar
• Winters CJr, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24
   PubMed Web of Science ®Google Scholar
• Murphy KG, Bloom SR. Gut hormones in the control of appetite. Exp Physiol 2004;89:507-16
   PubMed Web of Science ®Google Scholar
• Fernandez-Riejos P, Najib S, Santos-Alvarez J, et al. Role of leptin in the activation of immune cells. Mediators Inflamm 2010;2010:568343
   PubMed Web of Science ®Google Scholar
• Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor. OB-R. Cell 1995;83:1263-71
   PubMed Web of Science ®Google Scholar
• Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003;133:11-19
   PubMed Web of Science ®Google Scholar
• Kendall BJ, Macdonald GA, Hayward NK, et al. Leptin and the risk of Barrett’s oesophagus. Gut 2008;57:448-54
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Morgenstern H, McConell D, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology 2013;145:1237-44 e1-5
   PubMed Web of Science ®Google Scholar
• Beales IL, Garcia-Morales C, Ogunwobi OO, et al. Adiponectin inhibits leptin-induced oncogenic signalling in oesophageal cancer cells by activation of PTP1B. Mol Cell Endocrinol 2014;382:150-8
   PubMed Web of Science ®Google Scholar
• Mokrowiecka A, Sokolowska M, Luczak E, et al. Adiponectin and leptin receptors expression in Barrett’s esophagus and normal squamous epithelium in relation to central obesity status. J Physiol Pharmacol 2013;64:193-9
   PubMed Web of Science ®Google Scholar
• Howard JM, Cathcart MC, Healy L, et al. Leptin and adiponectin receptor expression in oesophageal cancer. Br J Surg 2014;101:643-52
   PubMed Web of Science ®Google Scholar
• Coe PO, O’Reilly DA, Renehan AG. Excess adiposity and gastrointestinal cancer. Br J Surg 2014;101:1518-31
   PubMed Web of Science ®Google Scholar
• Dvorak K, Chavarria M, Payne CM, et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett’s esophagus. Clin Cancer Res 2007;13:5305-13
   PubMed Web of Science ®Google Scholar
• Exley MA, Hand L, O’Shea D, et al. Interplay between the immune system and adipose tissue in obesity. J Endocrinol 2014;223:R41-8
   PubMed Web of Science ®Google Scholar
• Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-alpha in Barrett’s oesophagus: a potential novel mechanism of action. Oncogene 2002;21:6071-81
   PubMed Web of Science ®Google Scholar
• O’Sullivan KE, Reynolds JV, O’Hanlon C, et al. Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy? J Gastrointest Cancer 2014;45:1-11
   PubMedGoogle Scholar
• Hardikar S, Onstad L, Song X, et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett’s esophagus cohort. Cancer Epidemiol Biomarkers Prev 2014;23:2393-403
   PubMed Web of Science ®Google Scholar
• Allott EH, Lysaght J, Cathcart MC, et al. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation. Mol Carcinog 2013;52(2):144-54
   PubMed Web of Science ®Google Scholar
• Lysaght J, van der Stok EP, Allott EH, et al. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett 2011;312:62-72
   PubMed Web of Science ®Google Scholar
• Allott EH, Morine MJ, Lysaght J, et al. Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis. Clinical and translational gastroenterology 2012;3:e12
   Google Scholar
• Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56
   PubMed Web of Science ®Google Scholar
• Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012;142:442-52 e5
   PubMed Web of Science ®Google Scholar
• Schneider JL, Zhao WK, Corley DA. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett’s esophagus. Dig Dis Sci 2015;60:436-43
   PubMed Web of Science ®Google Scholar
• Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-96
   PubMed Web of Science ®Google Scholar
• Nguyen T, Tang Z, Younes M, et al. Esophageal COX-2 expression is increased in Barrett’s esophagus, obesity, and smoking. Dig Dis Sci 2015;60:65-73
   PubMed Web of Science ®Google Scholar
• Mobius C, Stein HJ, Spiess C, et al. COX2 expression, angiogenesis, proliferation and survival in Barrett’s cancer. Eur J Surg Oncol 2005;31:755-9
   PubMed Web of Science ®Google Scholar
• Moller DE, Flier JS. Insulin resistance–mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48
   PubMed Web of Science ®Google Scholar
• Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011;3:12
   PubMed Web of Science ®Google Scholar
• Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-6
   PubMedGoogle Scholar
• Rubenstein JH, Davis J, Marrero JA, et al. Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 2005;22:267-71
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6
   PubMed Web of Science ®Google Scholar
• Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol 2012;107:196-204
   PubMed Web of Science ®Google Scholar
• Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010;61:301-16
   PubMed Web of Science ®Google Scholar
• Donohoe CL, Doyle SL, McGarrigle S, et al. Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg 2012;99:387-96
   PubMed Web of Science ®Google Scholar
• Ek WE, Levine DM, D’Amato M, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. J Natl Cancer Inst 2013;105:1711-18
   PubMed Web of Science ®Google Scholar
• Su Z, Gay LJ, Strange A, et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet 2012;44:1131-6
   PubMed Web of Science ®Google Scholar
• Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 2013;45:1487-93
   PubMed Web of Science ®Google Scholar
• Dura P, van Veen EM, Salomon J, et al. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer 2013;133:1751-5
   PubMed Web of Science ®Google Scholar
• van Nistelrooij AM, van der Korput HA, Broer L, et al. Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. J Carcinog 2015;14:5
   PubMedGoogle Scholar
• Palles C, Chegwidden L, Li X, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology 2015;148:367-78
   PubMed Web of Science ®Google Scholar
• Gu Y, Lin S, Li JL, et al. Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion. Oncogene 2012;31:469-79
   PubMed Web of Science ®Google Scholar
• Sharma R, Prudente S, Andreozzi F, et al. The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides levels among diabetic subjects. Atherosclerosis 2011;216:157-60
   PubMed Web of Science ®Google Scholar
• Yiannakouris N, Cooper JA, Shah S, et al. IRS1 gene variants, dysglycaemic metabolic changes and type-2 diabetes risk. Nutr Metab Cardiovasc Dis 2012;22:1024-30
   PubMed Web of Science ®Google Scholar
• Qi Q, Bray GA, Smith SR, et al. Insulin receptor substrate 1 gene variation modifies insulin resistance response to weight-loss diets in a 2-year randomized trial: the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. Circulation 2011;124:563-71
   PubMed Web of Science ®Google Scholar
• Kilpelainen TO, Zillikens MC, Stancakova A, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 2011;43:753-60
   PubMed Web of Science ®Google Scholar
• Maglio C, Ericson U, Burza MA, et al. The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals. J Clin Endocrinol Metab 2013;98:E785-9
   PubMed Web of Science ®Google Scholar
• Thrift AP, Shaheen NJ, Gammon MD, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst 2014;106:11
   PubMed Web of Science ®Google Scholar
• Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013;273:219-34
   PubMed Web of Science ®Google Scholar
• Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 2012;35:2613-17
   PubMed Web of Science ®Google Scholar
• Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond) 2008;32 Suppl 7:S93-7
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653-62
   PubMed Web of Science ®Google Scholar
• Ashrafian H, le Roux CW, Darzi A, et al. Effects of bariatric surgery on cardiovascular function. Circulation 2008;118:2091-102
   PubMed Web of Science ®Google Scholar
• Kardassis D, Grote L, Sjostrom L, et al. Sleep apnea modifies the long-term impact of surgically induced weight loss on cardiac function and inflammation. Obesity (Silver Spring, Md) 2013;21:698-704
   PubMed Web of Science ®Google Scholar
• Himpens J, Cadiere GB, Bazi M, et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 2011;146:802-7
   PubMed Web of Science ®Google Scholar
• Kampe J, Brown WA, Stefanidis A, et al. A rodent model of adjustable gastric band surgery-implications for the understanding of underlying mechanisms. Obes Surg 2009;19:625-31
   PubMed Web of Science ®Google Scholar
• Peterli R, Borbely Y, Kern B, et al. Early Results of the Swiss Multicentre Bypass Or Sleeve Study (SM-BOSS): A Prospective Randomized Trial Comparing Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass. Ann Surg 2013;258(5):690-4
   PubMed Web of Science ®Google Scholar
• Singh S, Devanna S, Edakkanambeth Varayil J, et al. Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol 2014;14:101
   PubMed Web of Science ®Google Scholar
• Winzer BM, Paratz JD, Reeves MM, et al. Exercise and the prevention of oesophageal cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett’s oesophagus. BMC Cancer 2010;10:292
   PubMed Web of Science ®Google Scholar
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-54
   PubMed Web of Science ®Google Scholar
• Singh S, Singh AG, Singh PP, et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:620-9
   PubMed Web of Science ®Google Scholar
• Choi SE, Perzan KE, Tramontano AC, et al. Statins and aspirin for chemoprevention in Barrett’s esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) 2014;7:341-50
   PubMed Web of Science ®Google Scholar
• Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545-57
   PubMed Web of Science ®Google Scholar
• Jankowski JA, Hooper PA. Chemoprevention in Barrett’s esophagus: A pill a day? Gastrointest Endosc Clin N Am 2011;21:155-70
   PubMedGoogle Scholar
• Ohtani N, Yoshimoto S, Hara E. Obesity and cancer: a gut microbial connection. Cancer Res 2014;74:1885-9
   PubMed Web of Science ®Google Scholar
• Liou AP, Paziuk M, Luevano JMJr, et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 2013;5:178ra41
   PubMed Web of Science ®Google Scholar